Targeted Therapies Set to Transform Warm Autoimmune Hemolytic Anemia Care

For decades, patients with wAIHA have relied on corticosteroids, rituximab, and other nonspecific therapies that often lose efficacy or carry significant safety risks. With no specific regulatory approvals currently in place, the landscape is shifting toward mechanism-based treatments. Companies including Johnson & Johnson, Sanofi, and Novartis are leading this transition with advanced-stage candidates such as IMAAVY, WAYRILZ, and ianalumab. These therapies utilize FcRn inhibitors, BTK inhibitors, and BAFF-R signaling suppression to address the disease at its root, offering a potential new standard of care for refractory or relapsed patients.

The economic and clinical stakes remain high. In 2025, the wAIHA market across seven major regions reached approximately USD 600 million, with the United States accounting for 60% of that total. With an estimated 120,000 diagnosed prevalent cases, the demand for targeted innovation is acute. Analysts at DelveInsight note that the move toward distinct immunologic checkpoints, as seen in ongoing Phase III programs, reflects a strategic commitment to reducing reliance on broad-spectrum immunosuppressants. As regulatory filings for these novel agents move forward, the sector expects to fill significant gaps in care for patients who have exhausted traditional options.